[video]Did Novartis Overpay for AveXis?

Last week, Novartis (NYSE:NVS) paid a huge premium for gene therapy company AveXis. Of course, it's impossible to say for sure whether Novartis overpaid until more time passes, but there are still some signs that might hint to the answer now.